Therorna

Therorna was founded in China in 2021, leveraging its proprietary circular RNA technology platform to develop next-generation vaccines and innovative therapies.

Compared with linear RNA, circular RNA (circRNA) offers benefits in expression, stability, immunogenicity, and production. Thanks to its structure, circRNA as a tool for protein expression has been proven to maintain a relatively stable protein expression level in vivo for a longer time, which is expected to expand the application scenarios of RNA therapy.

Therorna raised Series A funding in June 2022 to help accelerate the development of a new broad-spectrum COVID-19 vaccine and the discovery of additional novel therapies for a variety of diseases. The company says it has already established a strong pipeline of novel prophylactic and therapeutic drugs aiming to address high unmet medical needs.

The company’s founder Wensheng Wei is a Professor at Peking University and previously also founded genome editing company EdiGene.

Subscribe for alerts on new companies featured on Startups.Bio

Function Oncology
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond measuring gene sequence to measuring …
Mallia Therapeutics
Founded in 2023, Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss. sCD83, which was discovered as an immune modulator by Mallia co-founder …
T-Therapeutics
T-Therapeutics is on a mission to unlock the power of T cells to treat chronic and infectious diseases. Founded in 2022, the company is based on technology from Professor Allan …
Empyrean Neuroscience
Empyrean Neuroscience has developed a platform for genetically engineering small molecule therapeutics from fungi and plants to treat neuropsychiatric and neurologic disorders. Through precision targeting and engineering of the fungal …

View all recently featured startups

Tags: